Module 17 2024

03/12/2024

Final decision

• 1.1The case for adopting HeartFlow FFR CT for estimating fractional flow reserve from coronary CT angiography (CCTA) is supported by the evidence. The technology is non-invasive and safe, and has a high level of diagnostic accuracy. • 1.2HeartFlow FFR CT should be considered as an option for patients with stable, recent onset chest pain who are offered CCTA as part of the NICE pathway on chest pain. Using HeartFlow FFR CT may avoid the need for invasive coronary angiography and revascularisation. For correct use, HeartFlow FFR CT requires access to 64-slice (or above) CCTA facilities. • 1.3Based on the current evidence and assuming there is access to appropriate CCTA facilities, using HeartFlow FFR CT may lead to cost savings of £214 per patient. By adopting this technology, the NHS in England may save a minimum of £9.1 million by 2022 through avoiding invasive investigation and treatment. (this hasn’t happened clinically, however the pandemic did force cost savings as fewer patients were treated) • https://www.nice.org.uk/guidance/mtg32/chapter/1-Recommendations

31

NICE MedTech recommendations

Product has potential to provide substantial benefits, but uncertainty about whether these are realisable in normal clinical settings Adoption optimised OR Research recommended

Evidence shows sufficient certainty of benefit

Significant uncertainty, or certainty of no benefit

Case supported

Case not supported

Use (with standard NICE implementation or “deeper” adoption support - NTAC)

Use in subgroup OR EAC supports development of evidence

Not for current use

32

16